ArticleInternational journal of molecular medicine2018
Knockdown of miR-194-5p inhibits cell proliferation, migration and invasion in breast cancer by regulating the Wnt/β-catenin signaling pathway.
Article in International journal of molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 34 citations in OpenAlex.
- LncRNA MIR99AHG serves as a diagnostic marker for early lung cancer and regulates cancer cell growth and metastasis via miR-194-5p.Discover oncology · 2025Article
- Examining the Role of Matrix Metalloproteinase-2 and MicroRNAs Regulation in Breast Cancer.The breast journal · 2025Review
- Hsa-miR-194-5p and hsa-miR-195-5p are down-regulated expressed in high dysplasia HPV-positive Pap smear samples compared to normal cytology HPV-positive Pap smear samples.BMC infectious diseases · 2024Article
- Plasma Circular-RNA 0005567 as a Potential Marker of Disease Activity in Rheumatoid Arthritis.International journal of molecular sciences · 2023Article
- MEF2C and miR-194-5p: New Players in Triple Negative Breast Cancer Tumorigenesis.International journal of molecular sciences · 2023Article
- Review
- Frailty in Aging and the Search for the Optimal Biomarker: A Review.Biomedicines · 2022Review
- Down-Regulation of miR-194-5p for Predicting Metastasis in Breast Cancer Cells.International journal of molecular sciences · 2021Article
- MicroRNAs and Extracellular Vesicles as Distinctive Biomarkers of Precocious and Advanced Stages of Breast Cancer Brain Metastases Development.International journal of molecular sciences · 2021Article
- Review
- Role of Long Non-Coding RNA LINC00641 in Cancer.Frontiers in oncology · 2021Review
- Determination of Genetic and Epigenetic Modifications-Related Prognostic Biomarkers of Breast Cancer: Genome High-Throughput Data Analysis.Journal of oncology · 2021Article
- Sry-related High Mobility Group Box 17 Functions as a Tumor Suppressor by Antagonizing the Wingless-related Integration Site Pathway.Journal of cancer prevention · 2020Review
- Long non-coding RNA LSINCT5 inactivates Wnt/β-catenin pathway to regulate MCF-7 cell proliferation and motility through targeting the miR-30a.Annals of translational medicine · 2020Article
- Detection of microRNA expression levels based on microarray analysis for classification of idiopathic pulmonary fibrosis.Experimental and therapeutic medicine · 2020Article
- Involvement of Differentially Expressed microRNAs in the PEGylated Liposome EncapsulatedMolecules (Basel, Switzerland) · 2020Article
- Potential miRNAs for miRNA-Based Therapeutics in Breast Cancer.Non-coding RNA · 2020Review
- Urinary Exosomal MicroRNAs as Potential Non-invasive Biomarkers in Breast Cancer Detection.Molecular diagnosis & therapy · 2020Article
- Downregulation of circulating miR 802-5p and miR 194-5p and upregulation of brain MEF2C along breast cancer brain metastasization.Molecular oncology · 2020Article
- New Advances in Canonical Wnt/β-Catenin Signaling in Cancer.Cancer management and research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a major public health concern, due to its increasing incidence and limited effective treatment. The present study aimed to investigate the expression of microRNA (miR)‑194‑5p and its roles in breast cancer. The expression levels of miR‑194‑5p and SRY‑box 17 (SOX17) mRNA were detected in breast cancer tissues and cell lines by reverse transcription‑quantitative polymerase chain reaction. The protein expression levels were determined by western blotting. In addition, MTT, colony formation, scratch and Transwell assays were use to evaluate the characteristics of MCF‑7 cells with miR‑194‑5p knockdown. The target verification of miR‑194‑5p was determined by luciferase reporter assay. Furthermore, tumor‑bearing nude mice with miR‑194‑5p knockdown were used to assess the effects of miR‑194‑5p on tumor activity. In breast cancer tissues, miR‑194‑5p was upregulated, whereas SOX17 was downregulated. In addition, the expression levels of SOX17 and phosphorylated (p)‑β‑catenin in the cytosol and nucleus were increased in the miR‑194‑5p inhibitor group. In addition, cell proliferation, migration and invasion were inhibited in response to miR‑194‑5p knockdown. The luciferase reporter assay confirmed that SOX17 was a target gene of miR‑194‑5p. In the mouse studies, knockdown of miR‑194‑5p suppressed tumor growth and promoted SOX17 expression in nude mice with breast cancer. These findings suggested that knockdown of miR‑194‑5p may increase the expression of SOX17 and regulate the Wnt/β‑catenin signaling pathway in breast cancer cells; therefore, miR‑194‑5p may be considered a potential target for breast cancer prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.